PLCG1 and schizophrenia: This study prioritized an abnormal response to thapsigargin at PLC-γ1 as the most relevant drug target based on being the most significant node in the drug-naïve patient vs. control comparison, normalization over the course of efficacious clinical antipsychotic therapy, correlation to schizophrenia risk allele loading at the sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2) risk locus10,62, concurrent activity in neuronal SH-SY5Y cells and parallel evidence of schizophrenia-like behavioral changes in animal models following forebrain-specific ablation of PLC-γ163.